Page 4 - திறந்த பரோபகாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from திறந்த பரோபகாரம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In திறந்த பரோபகாரம் Today - Breaking & Trending Today

PhD student awarded IBM PhD Fellowship | WSU Insider | Washington State University


April 29, 2021
Syrine Belakaria
Washington State University computer science doctoral candidate Syrine Belakaria is one of 16 students selected from around the world to receive the 2021 IBM Research PhD Fellowship.
The highly competitive fellowship recognizes and supports exceptional PhD students who are working on promising and disruptive technologies, according to the IBM website. The two-year fellowship provides funding as well as mentorship with an IBM researcher in which students collaborate on a research or technology project.
“As a PhD student, it is exciting to know that the research I am working on has potential for scientific impact as recognized by the external scientific community, and in this case, the IBM research institution,” Belakaria said. “This motivates me to continue with confidence in my research work.” ....

Partha Pande , Joan Berry , Syrine Belakaria , Jana Doppa , Research Phd Fellowship , Microsoft Research , Washington State University , University Of Idaho , School Of Electrical Engineering , International Conference On Machine , State University , Joan Berry Chair Associate Professor , Electrical Engineering , Computer Science , Open Philanthropy , International Conference , Machine Learning , பார்த்தா பாண்டே , ஜோன் பெர்ரி , மைக்ரோசாஃப்ட் ஆராய்ச்சி , வாஷிங்டன் நிலை பல்கலைக்கழகம் , பல்கலைக்கழகம் ஆஃப் ஐடஹோ , பள்ளி ஆஃப் மின் பொறியியல் , சர்வதேச மாநாடு ஆன் இயந்திரம் , நிலை பல்கலைக்கழகம் , ஜோன் பெர்ரி நாற்காலி இணை ப்ரொஃபெஸர் ,

Hepatitis C Drugs Boost Remdesivir's Antiviral Activity Against COVID-19


Hepatitis C Drugs Boost Remdesivir’s Antiviral Activity Against COVID-19
Drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures, according to new study. Illustration credit: Jenna Luecke/University of Texas at Austin.
AUSTIN, Texas Remdesivir is currently the only antiviral drug approved in the U.S. for treating COVID-19 patients. In a paper published this week in
Cell Reports, researchers from The University of Texas at Austin, Rensselaer Polytechnic Institute (RPI) and the Icahn School of Medicine at Mount Sinai showed that four drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures. ....

United States , Balasubramanian Harish , Kris White , Thomas Kehrer , Thomasb Acton , Gaetano Montelione , Adolfo Garc , Helena Moreno , Theresaa Ramelot , Catherine Royer , Khushboo Bafna , Robertm Krug , Romel Rosales , University Of Texas At Austin , Icahn School Of Medicine At Mount Sinai , Defense Advanced Research Projects Agency , Department Of Defense , National Institute Of Allergy , National Institutes Of Health , Rensselaer Polytechnic Institute , Cell Reports , Icahn School , Mount Sinai , Lisa Miorin , National Institutes , Computational Innovations ,